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deaths per annum.[2] Respiratory patho-
gens can be highly contagious and those 
with underlying respiratory or immune 
disorders are particularly at risk of death. 
This area of research is highly topical 
given the recent Severe acute respiratory 
syndrome coronavirus-2 (SARS-CoV-2) 
pandemic, which has reached over 
110 749 023 confirmed cases and 2 455 131 
deaths, as of February 21, 2021.[7] Thus, 
basic pulmonary drug research and biop-
harmaceutical development of respira-
tory therapeutics, antivirals and vaccines 
is of paramount importance. In order 
to deliver the most effective treatments, 
however, a fundamental understanding 
of human lung biology is required and 
with it, models which accurately repre-
sent the complexity found in vivo. This 
is especially important when coupled 
to the high drug attrition rates, time to market, and ethical 
concerns surrounding the use of animals in research, cur-
rently seen in drug R&D pipelines.[8–10] Other reviews exist 
with a specific focus on microfluidic[11] and in silico models 
for drug delivery, deposition, and pharmacokinetics in pre-
clinical lung models[12] as well as ex vivo tissue engineering 
for lung transplantation applications.[13,14] In this review, how-
ever, we discuss the function and cellular composition of the 
pulmonary epithelium barrier—the first line of respiratory 
defense. We then describe the pulmonary immune system, 
providing a primer on its response to common respiratory 
pathogen, and remodeling of the respiratory epithelium in 
disease (asthma and COPD). We will finish by presenting the 
most common in vitro models for studying host-respiratory 
pathogen interactions, advances in technology integrated 
models and future perspectives for studying these complex 
systems. Altogether, this review should provide the user with 
a basic biological understanding of the respiratory epithelial 
barrier and immune components required to study respira-
tory host–pathogen interactions in vitro. Additionally, it may 
be used as a reference point for understanding the require-
ments, relative merits, and drawbacks of using a variety of 
currently available in vitro lung models, ranging from 2D to 
complex 3D cultures. In the context of this review, 2D cul-
ture is defined as the growth of cell monolayers on a flat sub-
strate, for example, a petri dish or polymer membrane, while 
3D culture is defined as a tissue-specific microenvironment 
which allows cells to retain their in vivo 3D architecture and 
function, for example, spheroids, organoids and use of hydro-
gels, scaffolds, and bioreactors.
Respiratory diseases and lower respiratory tract infections are among the 
leading cause of death worldwide and, especially given the recent severe 
acute respiratory syndrome coronavirus-2 pandemic, are of high and preva-
lent socio-economic importance. In vitro models, which accurately represent 
the lung microenvironment, are of increasing significance given the ethical 
concerns around animal work and the lack of translation to human disease, 
as well as the lengthy time to market and the attrition rates associated with 
clinical trials. This review gives an overview of the biological and immuno-
logical components involved in regulating the respiratory epithelium system 
in health, disease, and infection. The evolution from 2D to 3D cell biology and 
to more advanced technological integrated models for studying respiratory 
host–pathogen interactions are reviewed and provide a reference point for 
understanding the in vitro modeling requirements. Finally, the current limita-
tions and future perspectives for advancing this field are presented.
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1. Introduction
Respiratory diseases are among the leading causes of death 
worldwide,[1] with more than 1 billion people suffering from 
long standing respiratory illness.[2] Among others, the most 
common conditions include asthma,[3,4] chronic obstructive 
pulmonary disorder (COPD),[5] and idiopathic pulmonary 
fibrosis,[6] where dysregulation, immune-hyperresponsive-
ness, and remodeling of the airway epithelium is evident. In 
addition to chronic respiratory disease, respiratory infection 
also contributes a substantial burden on society, especially 
lower respiratory tract infections which account for 4 million 
© 2021 The Authors. Advanced Biology published by Wiley-VCH GmbH. 
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1.1. The Respiratory System
The human respiratory system is responsible for essential 
breathing processes and gas exchange. Furthermore, the 
pulmonary epithelium constitutes a unique interface with the 
outside environment, acting as a physical and immunological 
barrier against noxious stimuli and pathogens. Its homeostatic 
functions include the dynamic regulation of ion permeability, 
transport of essential nutrients and antimicrobial secretion.[15] 
The respiratory system can be divided into the upper (nasal 
cavity, pharynx, and larynx) and lower airways (trachea, bronchi, 
bronchioles, alveoli, and lung parenchyma) (Figure  1). The 
lower airway can then be further sub-divided into three zones, 
according to the cellular phenotypes present: The proximal 
airway (trachea and bronchi) (Figure  1A), the bronchoalveolar 
duct junction (Figure 1B) and the alveoli (Figure 1C). The prox-
imal airway consists of a mucus layer, a thin surfactant layer, 
a periciliary layer, and the epithelial layer. Mucus consists of 
water (97%) with small amounts of lipids, carbohydrates, and 
proteins.[16] The most abundant proteins are mucins, secreted by 
goblet cells or submucosal glands, which give the mucus a gel 
like consistency and overall negative charge.[16] These character-
istics aid in capturing inhaled particles, toxins and pathogens, 
which are cleared from the respiratory tract via the coordinated 
beating of cilia (mucociliary clearance). Beneath the mucus, in 
contact with the cilia, is the periciliary fluid layer which contains 
anti-microbials, anti-virals, and anti-fungals.[17] Surfactant is an 
amphiphilic layer located between the mucus and periciliary 
fluid, containing predominantly phospholipids and cholesterol, 
with its main role to reduce surface tension and increase res-
piratory compliance. Surfactant is secreted in small amounts 
by club (formerly Clara) cells in proximal airways, although its 
major source of secretion is from alveolar type 2 pneumocytes.[17]
In addition to the aforementioned cell types, the proximal 
epithelium also comprises basal (stem) cells and pulmonary 
neuroendocrine cells (PNEC). Basal cells are responsible for 
epithelial regeneration upon damage, while PNECs are involved 
in neuroendocrine, exocrine, and immune signaling. The epi-
thelium not only regulates selective permeability, but also 
homeostatic levels of hydration by active transport through the 
epithelial sodium channel, the cystic fibrosis transmembrane 
conductance regulator channel, and the calcium activated chlo-
ride channel.[18] In contrast to proximal regions, the alveolar 
epithelium contains no ciliated cells nor does it secrete mucus, 
as this would reduce efficiency of gas exchange across the air-
blood barrier.[19] Instead, a surfactant fluid layer together with 
alveolar macrophages are responsible for the protection against 
inhaled irritants.[20,21] The Alveolar epithelium consists of type 
1 and type 2 pneumocytes, responsible for gas exchange and 
surfactant secretion, respectively. Type 2 cells also retain induc-
ible progenitor cell properties and, if the alveolar epithelium is 
damaged, can differentiate into type 1 cells.[22]
Figure 1. Cellular components of the lower airway pulmonary epithelium. A) The proximal (trachea, bronchi) airway epithelium consists of secretory 
club cells, ciliated cells, mucus producing goblet cells, basal stem cells, and pulmonary neuroendocrine cells. B) The distal portion of the lower airway 
consists of the bronchioles, the bronchoalveolar duct junction, and the alveoli. The bronchoalveolar duct is comprised of ciliated and club cells only. 
C) The alveolar epithelium consists of type 1 and type 2 pneumocytes. The blood circulation and immune cells also contribute to the defense mecha-
nisms via interaction with the pulmonary epithelium. Image created using BioRender.com.
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1.2. The Respiratory Immune System
It is increasingly recognized that the respiratory immune 
system plays a fundamental role in maintaining epithelial bar-
rier integrity and lung homeostasis, with disruption leading to 
the development of inflammation and disease. Additionally, 
the immune system contributes to barrier and protective func-
tions through the continuous sampling of the airway lumen for 
non-harmful, immunogenic, or pathogen derived antigens.[23] 
Table  1 summarizes the main airway epithelial and immune 
cell types responsible for epithelial barrier integrity and protec-
tion, with a brief description below.
As mentioned, airway epithelial cells (AECs) provide a phys-
ical barrier against the environment, but these cells also secrete 
a range of effector and regulatory molecules. These may take 
the form of mucins and surfactant proteins, which directly 
bind infectious agents and cell debris,[23] or reactive species, 
such as nitric oxide (NO), which may influence smooth muscle 
contraction[24] and activation of the adaptive immune response 
(Figure 2A,B).[23] AECs and dendritic cells (DC) display a range 
of specialized receptors capable of detecting self from non-self 
antigens.[25] Activation of these specific pattern-recognition 
receptors initiates various immunogenic and pathogen clear-
ance mechanisms including the early inflammatory response, 
recruitment of innate immune cells, and activation of the adap-
tive immune response.
During initial stages of pathogen invasion, the early inflam-
matory response is driven by the production of inflammatory 
Table 1. The main airway epithelial and immune cell types responsible for epithelial barrier integrity and protection.
Airway epithelial cell Epithelial barrier cell function Location in respiratory tract Pathogen defense role
Goblet cell Mucin production Proximal, distal airways and  
submucosal glands.
Mucin directly binds/traps pathogen and cell debris; 
Initiates microbial phagocytosis.[42,43]
Clara cell Surfactant production Proximal and distal airways. Surfactant directly binds/traps pathogen and  
cell debris; activates immune cells; initiates  
opsonization for pathogen clearance; Initiates  
microbial phagocytosis.[44,45]
Ciliated cell Ciliary movement and clearance of mucus Proximal and distal airways. Involved in the Muco-ciliary clearance mechanism and 
physical removal of cell debris and pathogens from 
respiratory tract.[46]
Alveolar type 2 cell Surfactant production and inducible 
progenitor for type 1 alveoli cells
Alveoli. Surfactant directly binds/traps pathogen and cell 
debris; activates immune cells; initiates opsoniza-
tion for pathogen clearance; Initiates microbial 
phagocytosis.[44,45]
Airway Immune cell Immune component Location in respiratory tract Pathogen defense role
Dendritic cells (DC) Innate immune system Conducting airways and alveoli.  
Send extensions trough mucosal  
epithelium to sample airway. Can migrate 
to regional lymph nodes, once activated.
Local non-specific inflammation; Detection of  
antigens; antigen presentation and priming  
of adaptive immune response.[35,47]
Neutrophil Innate immune system Conducting airways and alveoli. Phagocytosis; release of cytotoxic granules and  
neutrophil extracellular traps for pathogen entrapment; 
promotes recruitment of adaptive and innate immune 
system.[30]
Natural killer (NK) cell Innate and adaptive immune system Conducting airways and alveoli. Directly binds infected cells and promotes  
lysis/apoptosis; releases cytotoxic granules;  
promotes adaptive immune response.[27]
Macrophage Innate immune system Alveoli (90%) and conducting airways 
(10%). Quiescent macrophages attach to 
epithelial cells, activated macrophages 
circulate in airways.
Quiescent macrophages suppress the  
overstimulation of immune system; activated  
macrophages secrete cytokines, stimulate dendritic  
cells and phagocytose cell debris and pathogens; can 
also present antigens in some cases.[20,29]
T-cell Adaptive immune system. Naïve T-cells 
can differentiate into regulatory, helper, 
cytotoxic or memory T-cells
Naive T-cells located in lymph nodes  
and lymph tissue. Once activated,  
can circulate throughout airways  
and alveoli.
Regulatory T-cells suppress the overstimulation of 
immune system; Helper T-cell, for example, CD4+T  
regulate the adaptive immune response, especially 
B-cells and macrophages; cytotoxic T-cell, for example, 
CD8+ bind and lyse infected cells; memory T-cells 
remain and circulate after infection to ensure rapid 
response to reinfection.[35,37,48]
B-cell Adaptive immune system. Naïve B-cells 
can differentiate into plasma cells or 
memory B-cells
Naive B-cells located in lymph nodes  
and lymph tissue. Once activated,  
can circulate throughout airways  
and alveoli.
Plasma cells secrete specific antibodies which neutralize 
pathogens or bind and lyse infected cells; memory 
B-cells remain and circulate after infection to ensure 
rapid response to reinfection.[38,49]
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chemokines and cytokines alongside recruitment of neutro-
phils, dendritic cells, and natural killer (NK) cells to the site of 
infection (Figure  2A).[26,27] Phagocytic macrophages may also 
be recruited, however, the majority of respiratory macrophages 
reside in the alveoli (Figure  2B) rather than the conducting 
airways. Neutrophils, DCs, and macrophages are capable of 
working synergistically upon pathogen infection to promote 
airway inflammation, cytokine secretion, and lysis of viral-
infected cells.[28,20,29] Additionally, these innate immune cells are 
involved in the modulation of the adaptive immune response via 
induction of T-cells and enhancement of DC recruitment.[30,31,32]
Induction of the adaptive immune response is also propa-
gated through the ability of DCs to undergo a phenotypic change 
to present antigens.[33,34] Indeed, in response to respiratory 
Figure 2. Respiratory immune cell activation in response to pathogen invasion. Airway epithelial cells (AECs) and dendritic cells (DCS) continually 
sample airway lumen for either airborne pathogens or allergens. Activation of specific pattern-recognition receptors on the surface of DCs initiate an 
inflammatory cascade in the early stages of pathogen invasion, inducing chemokine, cytokine, and immunoregulatory compound, for example, nitric 
oxide (NO) production. A) Adaptive immune cells are also recruited to the site of infection and contribute to the inflammatory response as well as 
modulating the adaptive immune response. B) In the absence of mucus producing epithelial cells in the alveoli (which would otherwise slow down gas 
exchange), respiratory macrophages are the main resident immune cell type, performing a protective and phagocytic role. C) Antigen presenting DCs 
migrate to the lymph nodes, located throughout the proximal and distal lung regions, and prime naïve adaptive immune cells. Activated B- and T-cells 
then migrate to the site of infection or remain in peripheral circulation as memory cells. Image created using BioRender.com.
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infection, antigen-presenting DCs migrate to regional lymph 
nodes where they prime naive adaptive immune cells for dif-
ferentiation and proliferation (Figure 2C).[35] T-cell populations 
mitigate pathogen invasion via mechanisms specific to cell 
phenotype, including regulatory, cytotoxic, helper, and memory 
T-cell populations (Table  1). Briefly, regulatory T-cells are 
responsible for homeostatic regulation of the adaptive immune 
system[23], while cytotoxic T-cells directly bind and lyse infected 
cells. Memory T-cell population remain in blood circulation, 
lymphoid or lung tissues, with lung specific memory T-helper 
cells contributing to viral-mediated immunity upon reinfec-
tion.[36] B-cell populations, once primed, mitigate pathogen 
invasion via the production of specific antibodies, which induce 
lysis and apoptosis.[37] Specific memory B-cell populations also 
remain as long-lived plasma cells which persist in a quiescent 
state in many tissues.[38,39] Adaptive memory immune cell pop-
ulations decline over time, with the rate of decline dependent 
on pathogen type and environmental conditions, meaning the 
potential loss of immunity over time.[40,41]
It is also important to mention a unique immune compo-
nent, specific to mucosal surfaces such as the lung and gut: the 
mucosal immune system, also referred to as mucosal associ-
ated lymphoid tissue. In the event that pathogens evade the 
physical cellular barriers of the respiratory system, mucosal 
tissue has unique innate and adaptive immune mechanisms, 
similar, but separate from the peripheral lymphoid system.[16,23] 
Thus, the mucosal immune system provides an additional pro-
tective layer in respiratory infections.
2. Modelling the Respiratory System In Vitro
2.1. Cell Types
As with the study of other biological systems, murine models 
are the most extensively studied in respiratory homeostasis, 
pathology and immune regulation. Indeed rodent models offer 
a complete, functioning biological system. However, since the 
introduction of the 3Rs principles (reduce, replace, refine), orig-
inally proposed in 1959,[50] together with the cosmetic testing 
ban of 2013,[51] there have been increasing ethical concerns 
surrounding animal use for scientific research. Furthermore, 
rodent models often lack clinical translatability, with high drug 
attrition rates seen in many phase III clinical trials.[8–10] Thus, 
human derived in vitro models offer an alternative for bridging 
the translational gap and have been increasingly researched and 
developed in recent years. However, given the complexity and 
cellular heterogeneity of the repository epithelium throughout 
the airways, the specific pathogen, effector location, and dis-
eased/healthy phenotype should inform the cell types chosen to 
model respiratory host–pathogen interactions.
Many lung and immune-derived cell lines are available for 
culture, with the most commonly used listed in Table 2. Among 
the lung derived cell types, Calu-3 and A549 cell lines are most 
widely used. Calu-3 cells are derived from the submucosal gland 
of a human cancer patient, express vast numbers of goblet cell 
markers, differentiate into multiple cell types when cultured at 
the air liquid interface (ALI), and are useful for studying mucus 
production and mucociliary dysfunction. A549s, although 
commonly used to model the alveolar epithelial barrier, are 
derived from type 2 pneumocytes. These cells are secretory in 
nature and do not contribute largely to barrier formation.[52] 
Thus, other alveolar cell models, that represent the barrier 
forming type 1 pneumocytes, would be better suited for perme-
ability, diffusion or barrier disruption experiments. To date, only 
one cell line is available for modelling alveolar type 1 pneumo-
cytes (hAELVi cells),[53] with other attempts mainly involving the 
isolation and culture of type 2 cells to give type 1-like cell pheno-
types. Important to note, however, is the derivation of cell lines 
from cancerous tissue and their phenotypic representation of 
limited cell types. Thus, the use of primary cells is preferable in 
representing different cell type populations, signaling interplay 
and the patient heterogeneity found in vivo. However, primary 
cells are in limited supply and are more difficult to culture. The 
respiratory immune system must also be represented for in 
vitro models to fully reflect the in vivo respiratory barrier envi-
ronment. Among immune-derived cell types, the most widely 
used are those obtained from peripheral blood monocytes such 
as macrophages[54] and dendritic cells.[55] It is also possible to 
obtain tissue specific, resident immune cells such as those 
adhered to the epithelium or parenchyma of lung biopsies, the 
most commonly derived being alveolar macrophages.[56] How-
ever, the process of isolating these cells is much more time 
consuming and complex compared with obtaining them from 
blood. Immune cell lines which are derived from bone barrow 
of cancer patients are also available and, depending on the cul-
ture and stimulant conditions, it is possible to direct their differ-
entiation into multiple myeloid cell types. Although this pluri-
potency may be advantageous in obtaining and representing 
multiple immune cells types, the cancerous nature of their ori-
gins will likely not reflect healthy phenotypes found in vivo. The 
cell type(s) one chooses for modelling the lung depends on the 
specific application and experimental question to be addressed. 
Important points to consider are: Location along the respira-
tory track, cell phenotypes and populations to be represented, 
importance of epithelial barrier formation and type of cell secre-
tion or immune-cell signaling pathways under study.
2.2. Traditional Model Systems for Studying Respiratory 
Host–Pathogen Interaction
Having given an overview of the respiratory epithelial system, 
lung and immune cell types available, we now consider the 
range of traditional in vitro models available for studying the 
lung microenvironment, each with their own merits, draw-
backs, and benefit–cost ratio. Of important consideration is the 
societal need for having representative, reproducible in vitro 
platforms for the efficient discovery of virulence mechanism 
and development of antiviral vaccines for any future novel path-
ogens. Table 3 gives an overview of the traditional lung models 
available which are also briefly discussed below.
2.2.1. 2D In Vitro Models
Culturing a submerged cell line in 2D offers a relatively cheap 
and quick culture method (typically 3–5 days) which may be 
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advantageous for high throughput screening and assay develop-
ment. For example, a cell line may be cultured in a well plate, 
inoculated with an isolated virus of varying MOIs (multiplicity 
of infection) and plaque forming units measured from cell 
supernatant,[70] with the whole assay taking less than a week to 
perform. However, submerged cell culture does not reflect the 
native air interface of the respiratory system which can influence 
the differentiation and growth processes of cell culture.[58,61,71] 
Air-interfaced cultures are most appropriate in this context, with 
the supply of nutrients both apically and basally during differ-
entiation, and air lifting post-differentiation, reflecting the envi-
ronments and processes found in vivo. Additionally, ALI culture 
grown in a Transwell configuration provides a more in depth 
analysis of viral entrance. For example, it is possible to inoculate 
with infected serum, or using aerosol deposition atop the cell 
culture, mimicking entrance in vivo. Collecting cell superna-
tant both apically and basally, then permits the study and spatial 
identification of cell specific entrance with methods such as 3D 
immunofluorescence rendering and quantification as well as 
RNA extraction, viral plaque forming assays, and scanning elec-
tron microscopy.[72] Culturing primary cells in Transwell con-
figurations, and the formation of a pseudostratified epithelium, 
permits patient- and disease-specific studies of response to 
infection and therapeutics in 2.5D. Multiple cell types, such as 
epithelial, endothelial, or immune cells can also be co-cultured 
on either the basal or apical side on the Transwell filter insert, 
representing a more complex and complete model. Additionally, 
by using functional confocal microscopy and live capture video 
analysis, it is possible to obtain pathogen-induced measures of 
immune cell recruitment, receptor entrance, and transmigration 
through the membrane and cell layers.[73] Other gold-standard 
assays involve monitoring epithelial barrier integrity during 
pathogen challenge using trans-epithelial electrical resistance 
(TEER)[74] or ionic conductance.[75] However, important to note, 
is that primary cells are of limited supply and require a much 
longer culture, inoculation, and treatment period than cell lines 
(typically 4–6 weeks).
2.2.2. Toward 3D In Vitro Models
In contrast to 2D models, 3D models more accurately represent 
the physiological architecture found in vivo. For example, it is 
possible to provide structural, mechanical, and spatiotemporal 
Table 2. Cell types used for in vitro respiratory models.
Name Cell type Cell origin Use in modeling specific cell types
Respiratory system-derived
HNE[57] Primary cell Human primary nasal epithelial cells from patient 
brushings.
Nasal epithelial cells.
NHBE[58] Primary cell Primary human bronchial epithelial cells from patients. Bronchial epithelial cells.
Calu-3[59] Cell line Human adenocarcinoma cell line from 25-year-old male 
patient.
Bronchial epithelial cells.
16HBE140[60] Cell line Human bronchial epithelial cell line from a 1-year old 
male lung/heart transplant patient.
Bronchial epithelial cells.
A549[61] Cell line Human adenocarcinoma cell line from 58-year-old male. Alveolar type 2 cells.
hAELVi[53] Cell line Human alveolar epithelial cell line. Alveolar type 1 cells.
hAEpC[62] Primary cell Isolation and culture of type 2 human carcinoma 
alveolar epithelial cells.
Alveolar type 2 and type 1-like cells.
TT1[63] Cell line Transduced human type 2 carcinoma cells line  
(type 1-like phenotype).
Alveolar type 1 cells.
NCl-H441[64] Cell line Human type 2 carcinoma cell line. Alveolar type 2 cells.
Immune system-derived Use in modeling disease-associated inflammatory 
pathways
Macrophage[54] Primary cell Human peripheral blood monocytes. Macrophage induced phagocytosis and inflammation.
Dendritic cell[55] Primary cell Human peripheral blood monocytes. Dendritic cell induced inflammation.
Neutrophils[65] Primary cell Human peripheral blood. Neutrophil induced inflammation.
Alveolar macrophage[56] Primary cell Human lung tissue or bronchoalveolar lavage fluid. Macrophage induced phagocytosis and inflammation.
HL-60[66] Cell line Human acute promyelocytic leukemia cell line from  
a 36 year old women patient.
Spontaneous and directed differentiation into  
neutrophilic, monocytic, eosinophilic, and  
macrophage phenotypes.
THP-1[67] Cell line Human acute monocytic leukemia cell line from a  
1 year old male patient.
Spontaneous and directed differentiation into neu-
trophilic, monocytic, eosinophilic, and macrophage 
phenotypes.
HMC-1[68] Cell line Human acute systemic macrocytosis cell line. Mast cell induced inflammation.
LADR[69] Cell line Human acute systemic macrocytosis cell line. Mast cell induced inflammation.
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cues to the biological system, factors known to guide develop-
mental and differentiation processes.[76] Additionally, it is pos-
sible to recreate and study cell–cell and cell–extracellular matrix 
(ECM) interactions. An example of this, is the use of hydrogels 
in a range of tissue specific 3D models including lung organo-
genesis,[77] tumorigenesis,[78] and airway scaffolds.[79] Hydrogels 
Table 3. Most common in vitro respiratory models to study host–pathogen interactions.
Model type Advantages Disadvantages In vitro example of host pathogen 
interaction
Cell type(s) used
Submerged cell line culture – Easy to culture.
– 2–5 days culture period.
– Less skill required.
– Readily available/cheap.
– Representative of one cell type 
only.
– Usually a cancerous cell line.
– 2D culture.
– Not representative of air 
interface.
Respiratory syncytial virus[70] Bronchial cell line (BEAS-2B);  
Primary human nasal and bron-
chial epithelial cells.
ALI monoculture – Representative of air  
interfaced condition  
found in vivo.
– Permits the study of viral 
entrance and metabolic 
pathways apically and 
basally.
– More expensive.
– 3–4 weeks culture period with 
primary cells.
– 2D architecture.
SARS-CoV[72] Primary human alveolar type II 
cells.
SARS-CoV[92] Calu-3 cell line.
ALI co-culture – Most biomimetic static  
cell culture available.
– Representative of multiple 
cell types and systems 
found in vivo.
– 2.5D architecture.
– High level of skill needed to 
culture.
– 4–6 weeks culture period with 
primary cells.
Aspergillus (A.) fumigatus[73] Human primary bronchial 
epithelial cells, small airway cells, 
human blood derived macro-
phages, and dendritic cells.
Polymer scaffolds – Ability to house multiple  
cell types.
– 3D architecture.
– High level of skill and 
precision needed to slice and 
culture.
– Difficulty in monitoring cells 
within structure.
Influenza A[115] Human primary small epithelial 
cells.
Papain (mimics air bourne 
allergen)[81]
Calu-3 epithelial cell line, MRC-5 
fibroblast cell line, blood-derived 
dendritic cells.
Organoids – Derived from stem cells.
– Representative of the  
integrated tissue found  
in vivo.
– 3D structure.
– High level of skill needed to 
culture.
– 3–5 weeks culture period.
– Cant access/monitor apical 
and internal cell types without 
disrupting.
Parainfluenza[86] Human embryonic stem cells.
Respiratory syncytial virus[85] Human embryonic stem cells.
Multiple emerging influenza 
virus[91]
Tissue resident adult stem cells.
Precision cut lung slices (PCLS) – Fully differentiated tissue.




– Culture times are less than 
that of ALI culture.
– High level of skill and 
precision needed to slice and 
culture.
– Expensive and limited supply.
Influenza[88] Healthy lung slices from cancer 
patients undergoing lung 
resection.
Rhinovirus[89] Healthy and asthmatic lung slices 
from patient donors.
LPS (mimics bacterial 
infection)[90]
Lung slices from patients with a 
variety of medical conditions from 
the National Disease Research 
Interchange.
Cartoon insets created using BioRender.com.
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may be natural or synthetic and can be chemically, mechani-
cally, and physically tuned to their specific application. Synthetic 
hydrogels are made from materials such as polyethylene glycol, 
polylactic acid, poly(lactic-co-glycolic acid), polyvinyl alcohol, 
and polycarprolactone. Natural hydrogels are made from a com-
bination of polysaccharides, such as alginate, hyaluronic acid, 
agarose, chitosan, dextran, and cellulose, and proteins such as 
collagen, gelatine, fibrin, and poly-l-lysine (PLL). Matrigel is an 
example of a natural hydrogel, derived from Engelbreth-Holm-
Swarm mouse tumor basement membranes, that is widely 
used in tissue culture applications. The chosen materials, how-
ever, are based on trade-offs between biocompatibility, biodeg-
radability, homogeneity, and mechanical durability, each having 
their own advantage.
2.2.3. Polymer Scaffolds
Polymer scaffolds are commonly fabricated using electro-
spinning[80,81] or phase separation and freeze drying tech-
niques.[79,82,83] Scaffolds are seeded with lung cells and/or 
supporting immune and fibroblast co-cultures, providing a 
biomimetic lung architecture that permits cell movement 
and ECM-interaction. Furthermore, compared to 2D culture 
models, the use of scaffolds can increase the viability, differenti-
ation, and expression of phenotypic markers found in vivo.[79,83] 
3D scaffolds have been used to model respiratory infection[115] 
and immune response to allergens in lung disease,[81] with 
changes in epithelial barrier permeability, gene expression post-
inoculation observed. It is also possible to fix or lyse scaffolds 
for detailed microscopy analysis to observe any cell-scaffold 
interaction.[79] Although 3D polymer scaffolds pave the way for 
more representative models of lung tissue, they still hold some 
limitations such as heterogeneity of scaffold pore size and static 
cell culturing conditions.
2.2.4. Organoids
In contrast to cellular models, organoids represent a fully differ-
entiated 3D tissue structure. Lung organoid models are derived 
from human inducible pluripotent stem cells (iPSCs), embry-
onic stem cells, or ex vivo adult stem cells (ASCs) and may be 
grown at ALI or embedded within hydrogels.[84] Although 3D 
hydrogel organoid models are largely applied to the study of 
developmental processes[77] and signaling networks involved 
in the evolution of lung cancer,[78] they have been increasingly 
used in the field of respiratory disease, virology, and drug toxi-
cology testing. Pathogen inoculation proceeds by applying a 
viral solute or aerosol on top of Matrigel embedded lung orga-
noids,[85] while disease phenotypes may be induced by stimu-
lating organoids with disease-associated cytokine cocktails or 
via genetic modification of stem cells.[85] In response to infec-
tion, it is possible to image, in real time, the entrance site and 
migration of infection both locally, within specific cell types, 
and globally throughout the entire lung.[85–87] Furthermore, 
organoid models offer the advantage of being able to study cell–
ECM interaction, an important consideration when evaluating 
immune cell and pathogen interaction within the native organ. 
Organoids may also be co-cultured with human endothelial 
cells,[77] improving biomimicry and providing an opportunity 
to model vasculature-organ-ECM interactions and virulence 
of pathogens. However, a limitation still remains within these 
complex 3D organoid models in the inability to access or mon-
itor the apical or inner epithelium of the organoid.
2.2.5. Precision Cut Lung Slices
Another 3D model, representative of the native lung tissue, is 
precision cut lung slices (PCLSs). In contrast to cell and orga-
noid culturing methods that require lengthy culturing times 
for differentiation, PCLSs offer the advantage of retaining 
native tissue structure and specific macrophage populations. 
PCLSs have been used to study respiratory pathogen viru-
lence[88–90] as well as respiratory diseases, inflammation, and 
response to novel drug candidates.[91] However, like human 
primary cells, human PCLSs are limited in supply and last in 
culture for an average of 7 days compared to that of 21–28 days 
for ALI culture. Thus, they are unsuitable for long term expo-
sure studies.
Having given an overview and progression of traditional 
models for studying host respiratory processes, we now con-
sider, in more detail, the most common types of respiratory 
pathogen and how host–pathogen responses may be modeled 
in vitro.
2.3. Respiratory Disease and Infection
Many chronic autoimmune and lung diseases display aberrant 
immune and epithelial barrier function as hallmarks of their 
pathology. Here, we focus on asthma and COPD which, world-
wide, have the highest prevalence among respiratory diseases. 
Thus, understanding their underlying biomechanisms, co-
morbidities, and vulnerabilities are of high socio-economic and 
therapeutic importance. Although there is evidence for asthma-
COPD overlap syndrome,[93,94] highlighting the complex and 
interconnected mechanisms underlying their pathology, here 
the diseases will be discussed predominately in isolation.
2.3.1. Asthma
Asthma is characterized as a chronic inflammatory condition 
with concomitant remodeling of the proximal and distal air-
ways.[95] Although heterogeneities and subtypes exist, asthma 
can be broadly classified as intrinsic (non-allergic) or extrinsic 
(allergic),[96] with clinical presentation of exacerbation including 
shortness of breath, wheezing, cough and, in severe cases, 
airway obstruction and respiratory failure.[95] Many reviews 
exist on the molecular, immunological, and pathological 
mechanism leading to remodeling of the airway epithelium in 
asthma[3,4,95,97]; however, here we highlight models used to rep-
resent asthma in vitro.
Asthma may be modeled with the use of biopsies,[98] 
PCLSs,[99] or primary asthma cells grown at ALI.[100] Co-culture 
of asthmatic primary and immune cells may be used to study 
Adv. Biology 2021, 5, 2000624
www.advancedsciencenews.com
© 2021 The Authors. Advanced Biology published by Wiley-VCH GmbH2000624 (9 of 20)
www.advanced-bio.com
the crosstalk between the epithelium, immune system, and 
inflammatory signals in disease progression.[100] Additionally, 
tri-culture with epithelial, endothelial, and immune cell compo-
nents may be used to represent blood vessel compartments and 
signaling interplay between these cell types. Perfused culture 
systems are also useful in mimicking the native environment 
under flow, and have been increasingly used to studying lung 
inflammation, fibrotic remodeling, and response to therapeu-
tics.[101,102] Additionally, these systems may be used to study 
differences in healthy versus diseased airway response to envi-
ronmental triggers and drugs. Indeed, application of vaporized 
cigarette smoke, under flow, revealed previously undiscovered 
disease specific molecular signatures, potentially useful for 
future biomarker, and drug target studies.[103]
Asthmatic in vitro models successfully recapitulate aspects 
of the airway environment found in patients, for example, 
displaying fewer epithelial tight junction protein complexes, 
increased permeability, and increased sensitivity to environ-
mental triggers such as cigarette smoke.[104] Additionally, the 
use of patient samples means that the heterogeneity in disease 
severity will be represented when subjecting these systems to 
infection or novel therapeutics. This is highly relevant, given 
that respiratory infection is a major cause of asthmatic exac-
erbations.[105] Indeed, a body of evidence exists which argues 
that viral infection during childhood contributes to the initial 
pathogenesis of asthma.[106,107] Thus, modeling the interactions 
between the asthmatic pro-inflammatory environment, envi-
ronmental triggers, and pathogen-specific virulence, are fun-
damental in understanding and treating asthmatic population 
with an increased vulnerability to infection.
2.3.2. COPD
COPD is characterized as a progressive and chronic inflam-
matory disease, occurring in all parts of the lung including air-
ways, pulmonary vasculature, and lung parenchyma.[108] COPD 
shares some commonalties with asthma, for example, airway 
remodeling, chronic inflammation, and enhanced immune 
recruitment; however, COPD has its own defining features. In 
contrast to asthma, the airway remodeling that occurs in COPD 
is fibrotic, fixed, and irreversible[5,108] and, among environ-
mental factors, smoking has the largest influence on disease 
progression.[109] Substantial epithelial and endothelial apoptosis 
is present[110] and, in advanced stages, COPD exacerbations can 
lead to hyperventilation, hypoxia, and respiratory failure.[111,112] 
Reviews exist which describe the inflammatory and molecular 
mechanisms behind COPD pathology in detail[5,108,113]; however, 
here ways to model COPD are highlighted.
Often, patient biological samples are taken in the form of 
blood, bronchoalveolar lavage,[76,114–116] biopsies,[117,118] and cell 
brushings.[79,80,119] These are used to study levels of inflamma-
tory markers and immune cell activity, which may also form 
the basis for patient stratification and treatment. It is also pos-
sible to study markers of mucociliary clearance, such as levels 
of ciliary metaplasia[80,120] and ciliary beat frequency,[79] the 
reduction of which may increase patient vulnerability to infec-
tion and sputum production. An altered respiratory microbiota 
is also implicated in COPD pathophysiology,[121] with acute 
exacerbations linked to microbial–pathogen interactions and 
infection.[122,123,124] Mechanisms underlying these findings may 
be recapitulated using in vitro models of COPD, cultured with 
primary cells. For example, oxidative mechanisms,[125] and an 
enhanced inflammatory environment[126] have been shown to 
augment epithelial cytokine and specific recognition receptor 
expression in viral-induced COPD exacerbations. Additionally, 
to account for the increased risk of smokers developing COPD 
and viral-induced exacerbations, mechanisms behind smoke 
induced epigenetic changes in bronchial epithelium have also 
been explored, such as an increase in mesenchymal markers[127] 
and a decrease in antiviral cytokine expression.[128] These in 
vitro COPD models also serve the purpose of high throughput 
drug development for disease related complications, such as 
viral induced exacerbations,[127] highlighting the potential for 
personalized therapeutics based on disease heterogeneity and 
severity.
So far we have considered the respiratory epithelial and 
immune systems in health and in diseases such as COPD and 
asthma. Next, we discuss specific pathogen virulence mecha-
nisms, the altered host response to infection, and how this 
interplay may be modeled in vitro.
3. Respiratory Pathogens
The presence and accumulation of pathogens within the respir-
atory system can perturb homeostasis by overcoming the epi-
thelial barrier and eliciting an immune response. Despite the 
overlap of symptoms and clinical manifestations of respiratory 
infections, individual pathogen types and species have distinct 
modes of entrance and virulence (Table 4), with the host envi-
ronment and health status influencing severity and vulnerability 
to infection. Respiratory infection may be modelled in vitro by 
inoculating the cell culture system with isolated pathogen parti-
cles or with immunostimulants which mimic pathogen-specific 
inflammatory processes. Important considerations in choosing 
a model pathogen is whether the cell model expresses the rel-
evant pathogen-specific receptor, the respiratory location which 
the pathogen infects, and the experimental readouts you wish 
to use to assess virulence. Here, a brief overview of the most 
prevalent viral, bacterial, and fungal respiratory pathogens are 
given, together with their application in in vitro culture systems 
for studying respiratory host–pathogen interaction.
3.1. Viral Pathogens
Viral infection may be replicated in vitro by incubating cell 
culture systems with an immunostimulant which mimics 
viral inflammatory processes such as polyinosinic:polycytidylic 
acid (Poly I:C),[129] or by isolating live viruses and adminis-
tering them in serum or aerosol deposition. Viral isolation first 
requires sampling and collection from an infected biological 
specimen, such as a nasal swab, which is then grown in vitro by 
infecting cells (typically mammalian cells), as viral replication 
requires a host. Media from infected cells can then be collected 
and separated from cells via filtration or centrifugation, as a 
source or virus particles.[130] Common viral pathogens cultured 
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in this way include Corona viruses, influenza, respiratory syn-
cytial virus (RSV), and rhinoviruses which are listed in Table 4 
and briefly discussed below.
Corona viruses are classified into four types (alpha, beta, 
gamma, and delta) with Middle Eastern respiratory syndrome 
coronavirus (MERS-CoV), severe acute respiratory syndrome 
Coronavirus (SARS-CoV), and SARS-CoV-2; all of different lin-
eages within the beta category. Corona viruses infect epithelial 
cells of the upper and lower respiratory tract via viral spike pro-
tein binding and cleavage by host cell proteases. MERS-CoV 
enters via the CD26 receptor[131] while both SARS-CoV[132] and 
SARS-CoV-2[133] enter via the angiotensin converting enzyme 
2 (ACE 2) receptor. In the case of novel pathogens, such as 
recently emerged corona viruses, it is essential to recapitulate 
infection in a representative in vitro model, to gain insight into 
the mechanisms of transmission, pathogenesis, and possible 
targets for vaccines. The specific mode of entrance and viru-
lence have been studied in coronaviruses using cell lines,[92,134] 
primary cells,[72,134] and patient biopsies.[135] For example, the 
apical entrance of coronavirus in bronchiole epithelial cells, via 
the ACE 2 receptor, has been shown by protein co-localization 
in confocal Z-Stack immunofluorescence imaging.[92] Apical 
entrance and release of virions may also be demonstrated 
by sampling supernatant from apical and basolateral serum 
as well as via transmission electron microscopy imaging 
(Figure 3A).
Table 4. The most common viral, bacterial, and fungal pathogens known to cause repository infection.
Pathogen Clinical symptoms (complications) Respiratory tract infected part Pathogen entrance mechanism
Viral
MERS-CoV Fever, chills, sore throat, cough, shortness of 
breath, headache, vomiting, diarrhoea, myalgia 
(pneumonia, septic shock, severe acute  
respiratory distress syndrome, respiratory failure, 
multi-organ failure).
Upper and lower respiratory tract. Cell mediated membrane fusion or  
endocytosis via CD26 receptors.[131]
SARS-CoV Fever, chills, myalgia, shortness of breath  
(pneumonia, fibrosis, severe acute respiratory 
distress syndrome, respiratory failure).
Upper and lower respiratory tract. Cell mediated membrane fusion or  
endocytosis via ACE2 receptors.[132]
SARS-CoV-2 (COVID-19) Fever, chills, cough, shortness of breath, sore 
throat, rhinorrhoea, temporary anosmia or 
ageusia (pneumonia, septic shock, severe acute 
respiratory distress syndrome, respiratory failure, 
multi-organ failure).
Upper and lower respiratory tract. Cell mediated membrane fusion or  
endocytosis via ACE2 receptors.[133]
Seasonal influenza Fever, sore throat, cough, headache, rhinorrhoea, 
myalgia, headache, (laryngotracheobronchitis, 
bronchitis).
Upper respiratory tract. Cell mediated membrane fusion via sialic 
acid containing receptors and protease 
cleavage.[136]
Respiratory syncytial virus (RSV) Fever, sore throat, cough, headache, rhinorrhoea, 
shortness of breath, wheezing, (laryngotracheo-
bronchitis, bronchitis).
Lower respiratory tract. Cell mediated envelope fusion via 
nucleolin containing receptors.[137]
Rhinovirus Sore throat, cough, rhinorrhoea (bronchitis). Upper respiratory tract. Cell mediated endocytosis via ICAM-1, 
LDL or CDHR3 receptors.[169]
Bacterial
Streptococcus pneumoniae Fever, chills, cough, shortness of breath, chest 
pain, (pneumonia, septic shock, bacteraemia, 
meningitis).
Forms part of upper respiratory  
tract flora but can migrate and cause  
infection in lower respiratory tract and/ 
or spread systemically.
Extracellular colonization;  
polysaccharide capsule promotes  
adherence and protection.[144]
Haemophilus influenzae Fever, chills, cough, shortness of breath, chest 
pain, (pneumonia, bronchitis, septic shock, 
bacteraemia, meningitis).
Forms part of upper respiratory  
tract flora but can migrate and  
cause infection in lower respiratory  
tract and/or spread systemically.
Internalization by epithelial cells via 
micropinocytosis and rearrangement of 
epithelial cytoskeleton[141]; internalization 
by macrophage and neutralizes lysosomes 
to prevent detection or lysis.[147]
Mycobacterium tuberculosis Fever, chills, chest pain, cough, weight loss  
(meningitis, respiratory failure, multi-organ 
failure).
Lower respiratory tract and can spread 
systemically.
Internalization by macrophages via 
phagocytosis and neutralizes lysosomes to 
prevent detection or lysis; able to survive 
indefinitely but erupts to cause infection 
when host is immunocompromised.[150,151]
Fungal
Aspergillus (mold; most common 
species A. fumigatus)
Fever, chills, shortness of breath, wheezing, 
headache, cough, (Rhinitis, bleeding of the lungs, 
systemic infection, and multi-organ failure).
Upper and lower respiratory tract can 
spread systemically.
Can invade tissues by extending hyphae 
through endothelial and epithelial 
barriers.[142,168]
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Influenza viruses infect epithelial cells of the upper res-
piratory tract, via binding of viral hemagglutinin to sialic acid 
containing receptors of target cells.[136] The symptoms elicited 
following infection are due largely to the release of proinflam-
matory cytokine and chemokines for example interferons 
and tumor necrosis factor from viral-infected cells. In vitro, 
emerging strains of influenza may be studied in order to elu-
cidate replication and infectivity mechanisms as well as strain 
specific cytokine/chemokine profiles.[87,88]
RSV infects cells of the lower respiratory tract via binding 
of viral fusion glycoprotein with Nucleolin containing surface 
receptors of target cells.[137] RSV is easily transmitted and is a 
major cause of respiratory infection in children and infants. In 
vitro, the link between RSV virulence, airway hyperresponsive-
ness, and the production of specific cytokine profiles may be 
modeled using cell lines,[138] organoids,[85] or primary culture 
derived from pediatric patients populations.[139] RSV infection 
of lung specific immune cells has also be used to study cross-
talk between immune cell and epithelial components for both 
pathogen virulence and protection mechanisms.[70]
Rhinoviruses are one of the most common causes of the 
common cold and exacerbations in lung disease such as 
asthma. Rhinoviruses have three species (A, B, and C) with 
infection occurring in epithelial cells of the upper respiratory 
tract. Rhinovirus induced asthmatic exacerbations may be 
modeled in vitro models by comparing healthy and asthma 
derived primary cells[125,140] or lung slices[89] from patients and 
observing disease or patient specific inflammatory cytokine 
profiles as well as cell specific immune cell migration. Find-
ings from in vitro studies such as these may then be replicated 
and correlated to in vivo investigations to assess translatability 
to the human condition, a principle factor in improving drug 
development and therapeutics in the clinical setting.
3.2. Bacterial Pathogens
Bacterial infection may be replicated in vitro by incubating 
cell culture systems with an immunostimulant which mimics 
bacterial inflammatory processes such as Lipopolysaccha-
rides (LPS) or endotoxins.[143] In contrast to a live virus, bacteria 
do not require host cells for replication, rather, growth and iso-
lation of specific strains may be acquired using selective agar 
or media. Common respiratory bacterial pathogens cultured in 
this way include Streptococcus pneumoniae, Mycobacterium tuber-
culosis, and Haemophilus influenzae (Table 4).
S. pneumoniae commonly forms part of the upper respiratory 
tract flora and its presence is asymptomatic in most healthy 
individuals. However, under favorable environments or in com-
promised individuals, S. pneumoniae colonizes extracellular res-
piratory space, migrate to the lower respiratory tract and is the 
major cause of bacterial pneumonia in vulnerable patients. Vir-
ulence is associated with the release of invasion proteins such 
as pneumolysin, which contribute to host cell entrance and 
death via pore formation, toxin-induced apoptosis or induction 
of host cell epigenetic changes.[144] S. pneumoniae infection is 
also shown to decrease mucocilary clearance mechanisms and 
induce epithelial autolysis in primary respiratory organoid and 
biopsy samples.[145] Cell line models have also been useful as a 
high-throughput means for identifying novel targets and devel-
oping alternative treatments for resistant strains.[146]
Similar to S. pneumoniae, H. influenzae may be present in 
the upper respiratory tract flora and is an opportunistic path-
ogen, causing infection in vulnerable or immunocompromised 
Figure 3. Examples of in vitro models used to study entrance and virulence 
mechanisms of A) viral, B) bacterial, and C) fungal pathogens. A) Apical 
entry and release of severe acute respiratory syndrome-associated cor-
onavirus in polarized Calu-3 lung epithelial cells. Above: Transmission 
electron microscopy of release of SARS-CoV virons from the apical sur-
face of polarized Calu-3 cells. Below: Colocalization of ACE-2 and viral 
antigen in infected Calu-3 cells, both ACE-2 (green) and viral antigen 
(red) could be detected in infected cells. Importantly, both ACE-2 and 
viral antigen appeared to colocalize in infected cells (yellowish). Repro-
duced with permission.[92] Copyright 2005, ASM. B) Infection of primary 
human bronchial epithelial cells by Hemophilus influenzae. Above: Images 
collected by dual-wavelength CLSM of cells infected for 3 h; colocalization 
of airway nuclei, bacteria (green) and vacuoles (red) can be seen in yellow, 
suggesting bacteria have been taken into the cells. Scale bar is 50 µm. 
Below: The series (A through F) demonstrates lamellipodia surrounding 
bacteria (black arrow) at the surface of a submerged airway cell culture 
after 4 h of infection. Reproduced with permission.[141] Copyright 1999, 
ASM. C) Polarized response of endothelial cells to invasion by Aspergillus 
fumigatus. A. fumigatus hyphae invade the abluminal and luminal surface 
of endothelial cells by different mechanisms. Above: Hyphae invading the 
abluminal surface of endothelial cells, Arrows indicate an endothelial cell 
that is being invaded by a hypha. Below: Hyphae invading the luminal sur-
face, arrows indicate endothelial cell pseudopods. Hyphae are shown in 
green and microfilaments in red. Bars represent 5 µm. Reproduced with 
permission,[142] Copyright 2009, Wiley. The inset cartoon schematics rep-
resent the type of model chosen. Cartoon insets created using BioRender.
com.
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individuals by migrating to the lower respiratory tract and/or 
systemically. Virulence is caused by surface Lipooligosaccharides 
and lipoproteins, which when attached to the mucosal surface, 
exert disruptive effects on cilia function.[147] H. influenzae also 
produced proteases which help to evade macrophage induced 
lysis via mechanisms similar to that of M. tuberculosis. Virulence 
mechanism such as these have been studied in vitro by infecting 
cell lines.[148,149] It has also been shown that infection occurs via 
the rearrangement of epithelial cytoskeletons and micropino-
cytosis, demonstrated by microvilli and lamellipodia extending 
and engaging with bacteria, and the presence of bacteria within 
vacuoles of epithelial cells, respectively (Figure 3B).[141]
M. tuberculosis infects the lower respiratory tract and is the 
causative agent of tuberculosis. Infection occurs via macro-
phagic phagocytosis and contaminant neutralization of lys-
osomes. M. Tuberculosis is able to lie dormant within these cells, 
erupt when the host is immunocompromised and even cause 
chronic infection. Virulence of M. Tuberculosis is associated 
with the production of toxins, such as tuberculosis necrotizing 
toxin,[150] encapsulation in a lipid containing coating, and par-
ticipation in lysis-evading mechanisms.[151] Replication mecha-
nisms have been studied in human alveolar cell lines[152–155] and 
in co-culture with immune cell and ECM components.[156,157]
In addition to complications caused by primary bacterial 
infections, viral infection also increases the risk of developing 
a secondary bacterial infection, termed a bacterial superinfec-
tion.[47] Mechanisms behind this include viral-induced desensi-
tization of macrophages[158,159] and an impaired neutrophil and 
monocyte response.[47] Viral-induced epithelial damage may 
also facilitate the passage and colonization of bacterial patho-
gens within the respiratory tract and lung parenchyma. Further-
more, it is important to consider the respiratory microbiome in 
influencing a patient’s susceptibility and response to infection. 
Many reviews exist which describe the complex interaction 
between the respiratory microbiome, epithelium, and immune 
system,[160–163] but in brief, the microbiome is influenced by a 
range of early life experiences such as mode of delivery, envi-
ronment, diet, and respiratory infection. Additionally, the pres-
ence of underlying disease, immunosuppression, or certain 
drug treatment may influence microbiota profile, potentially 
leading to an inflammatory environment. Under these condi-
tions, commensal microbial species may become pathogenic, 
such as those mentioned above, for example, S. pneumoniae, 
H. influenzae. Conversely, commensal respiratory bacteria may 
also have a protective effect. For example, H. influenza, which 
is a common cause of respiratory infection in children, may 
offer specific protective roles against developing RSV.[164] Addi-
tionally, patient-specific microbiota profiles have been linked 
to having protective affects against influenza infection and 
virulence.[165] Therefore, the interaction between commensal 
and pathogenic microbes, within the respiratory system, are 
an important consideration when assessing patient specific 
responses to infection and therapeutics.
3.3. Fungal Pathogens
Like bacteria, fungal species may live in symbiosis with a host 
and, although possible to inhale infectious fungal agents, most 
infections are of the opportunistic type, developing disease 
mainly in immunocompromised individuals.[166] Fungi replica-
tion occurs via spore spreading and, like bacteria, can be grown 
and isolated in vitro using selective agar or media.
A. fumigatus is the most common respiratory fungal species 
and is associated with development of aspergillosis. Aspergil-
losis may take a variety of forms. Allergic aspergillosis occurs 
when patients experience an allergic reaction to fungal spores 
and is most common in patients with underlying inflamma-
tory lung conditions asthma and cystic fibrosis. Acute invasive 
aspergillosis on the other hand, is the most severe form of the 
disease and occurs in immunocompromised patients when 
the infection spreads systemically to other organs. Virulence of 
A. fumigatus occurs through the production of toxins such as 
Aflatoxin and Gliotoxin which exert immunosuppressive effects 
including disrupting cilia function, inhibiting phagocytosis, 
and inducing apoptosis.[167] In vitro models of A. fumigatus have 
demonstrated Hyphae extensions are capable of penetrating 
pulmonary endothelial and epithelial cells as a mechanism of 
invasion.[142,168] Additionally, hyphae invasion induces a polar-
ized response in endothelial cells, such that luminal inva-
sion occurs via endocytosis and the formation of pseudopods, 
whereas abluminal invasion occurs via the disruption of micro-
filaments (Figure 3C).
The evidence provided thus far encompasses studies which 
use traditional in vitro models of respiratory infection; how-
ever, in the hope of providing more relevant, biomimetic, and 
high throughput drug discovery platforms, a range of more 
advanced and technology integrated model systems are con-
tinuously being developed. These are discussed in detail below.
4. Advances in Technology Integrated Models for 
Studying Host Pathogen Interaction
In parallel to the growing ethical concerns surrounding animal 
use in research and their lack of their clinical translatability,[8–10] 
there has been a surge in the development of technology inte-
grated 3D in vitro models which better reflect the human in 
vivo lung condition. For example, it is possible to integrate 
previously static 2D, 2.5D, and 3D models, for example, ALI 
co-culture, organoids, etc. (as discussed in Section 4) with tech-
nological advances such as perfusion chambers[73,170] and lung-
on-chips.[101,171,172] Technology integrated biological systems have 
advanced knowledge surrounding the effect of culturing condi-
tions and model architecture on relevant parameters such as 
cellular differentiation, immune cell recruitment, and cytokine 
profile, such that lung models are becoming increasingly, and 
more accurately, representative of the human condition. Here, 
we discuss the progression from perfusion bioreactor chambers 
to microfluidics and sensor integrated lung-on-chips, and how 
these have advanced our understanding of lung cell culture.
4.1. Lung-on-Chip
With the development of fluidics and commercially available 
perfusion chambers, it is possible to accelerate the speed of 
growth, differentiation, and development of 2D lung epithelial 
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ALI models. Indeed, with perfusion systems, ciliogenesis, 
mucus production, and barrier formation are observed up to 14 
days earlier when compared to static culture.[73] Systems such 
as these enable the fast-track addition of immune co-culture 
and pathogen infection studies, significantly shortening experi-
mental protocol times without sacrificing the complexity of a 
3D ALI model. In parallel, the revolutionary development of 
microfluidic organ-on-chip technology during the last decade 
permits the coupling of microfluidics with microsensor tech-
nologies. Indeed, in addition to applying effective shear stress 
and flow, which enhances cellular differentiation,[173] sample 
preparation, and delivery of nutrients,[101] it is possible to inte-
grate on-chip biosensors such as pH sensors, microscopes, and 
electrodes.[172,174] In comparison to traditional culture systems, 
this enhances the speed of detection, breadth of readout data, 
device portability, and accelerates the point of care diagnostics.
Organ-on-chips are commonly microfabricated 
from transparent and biocompatible polymers such as 
poly(dimethylsiloxane (PDMS) and poly(methlymethacrylate) 
(PMMA), via soft lithography-based techniques, and consist of 
multiple layers of cell culture chambers integrated with micro-
fluidic perfusion systems. A pivotal study carried out by Huh 
and colleagues in 2010 involved the development of a novel 
actuation system which mimicked breathing in the human 
lung.[171] This “breathing lung-on-chip” consisted of an upper 
and lower chamber, separated by a thin porous PDMS mem-
brane. The upper compartment contained human alveolar 
epithelial cells cultured at air interface, while the lower com-
partment contained human microvascular endothelial cells 
co-cultured with human neutrophils under dynamic flow. 
Together, these compartments represented the alveolar cap-
illary lung unit which, under the application of a vacuum in 
adjacent chambers, underwent cyclically stretching repre-
sentative of physiological breathing (Figure  4A). Importantly, 
this study demonstrated the effect of breathing on enhancing 
inflammatory and immune signaling in primary co-culture. For 
example, when exposed to air pollutant extracts, an increase 
in pro-inflammatory adhesion molecules and reactive oxygen 
species was observed, when compared to static cell culture. 
Similar lung-on-chip models, which utilize an actuated micro 
diaphragm to induce mechanical breathing, also demonstrate 
a breathing-induced increase in barrier permeability, metabolic 
activity, and wound healing in lung epithelial cells.[175] These 
examples highlight the importance of representing in vivo like 
breathing forces when assessing the extent of inflammation 
and immune cell activation that an airborne particle, pathogen, 
or drug candidate could have. Additionally, improvements in 
design and fabrication methods permit passive, rather than 
active, perfusion of chips. This reduces the need for additional 
external equipment and tubing, while improving reproduc-
ibility.[176] Modern chip technology is also becoming increas-
ingly compatible with standard characterization methods such 
as TEER, enzyme linked absorbency assays (ELISA), and per-
meability assays,[176] making their integration into mainstream 
laboratories more amenable.
In another study, focusing on the effect of smoking induced 
respiratory inflammation and disease progression, a novel 
multi-compartment robotic smoking machine was micro-
engineered.[103] This replicated all major aspects of physi-
ological breathing including mechanical inhalation of smoke, 
controlled respiration parameters (respiration cycle, puff time, 
and inter puff interval), and flow rate over an air interfaced 
lung-on-chip. Compared to traditional exposure protocols, 
which deposit cigarette smoke extracts on top of cell culture, 
this study applied whole cigarette smoke under physiologi-
cally flow. This novel protocol revealed novel disease specific 
molecular signatures, potentially useful for future biomarker 
and drug target studies. Additionally, this study gave a detailed 
insight into smoke-induced changes in ciliary beat frequency 
distribution, which may be linked to reduced mucociliary 
clearance observed in smokers. With advances in fabrication 
methods, it is also possible to create complex 3D microchannel 
networks, within lab-on-chip systems. Indeed, Schnirman and 
colleagues[177] fabricated an anatomically inspired microfluidic 
model, mimicking the bifurcation networks of human alveolar 
tree structures which matched functional residue capacity 
values of pediatric populations (Figure 4B). Although complex 
structural models such as these are technically challenging to 
implement, they are fundamental in replicating and simultane-
ously studying the full breadth of cell types present in all parts 
of the airway. Models such those described above more fully 
recapitulate the human condition compared to traditional cell 
models and, although difficult to implement, are essential in 
reducing animal research and drug attrition rates.
Biomimetic 3D lung-on-chip models have also been increas-
ingly applied to the study of pathogen invasion, disease-
associated inflammation, host–pathogen interaction, and 
therapeutic treatment of novel infectious agents. Unlike tradi-
tional in vitro models of pathogen invasion, which involve the 
direct measurement of pathogen-induced effects upon epithe-
lial layers, chip systems are able to physically compartmentalize 
and connect different cell and microbial populations. Thus, 
it is possible to study more complex interactions between the 
host and pathogen under physiological flow. It is also possible 
study the communication that occurs between the lung ECM, 
immune system, and circulating volatile compounds at ALI. 
Indeed, Barkal and colleagues[168] microengineered an inno-
vative bronchiole-on-chip device which contained a central 
airway lumen and adjacent endothelial lumens connected via 
a fibroblast-collagen matrix (Figure  4C). A separate ”clickable” 
module, seeded with compartmentalized infectious microbials, 
was attached to the main lung unit. This was used to study 
pathogen-derived volatiles on the respiratory epithelium. In 
this instance, co-infection with the fungal and bacterial agents 
A. fumigatus and P. aeruginosa, respectively, was shown with 
hyphae extensions and leukocyte migration clearly observed 
at the site of infection (Figure  4C(III)). Lung-on-chip devices 
have also been used to study lung epithelial permeability[172,175] 
and single-strain pathogen infection.[171,163] Pathogen-induced 
effects on lung epithelial permeability may be measured via 
TEER or passage of fluorescently labelled molecules through 
the epithelium.[172,179] Additionally, cell effluent can be collected 
and assayed via ELISA or PCR for relative change in cytokine 
profile.[163] In the case of co-culture, immune cell migration to 
the site of infection may be observed via high resolution and 
real-time microscopy imaging.[171]
As well as modelling inflammation and immune recruitment 
in healthy lungs, lung-on-chip devices are also used to model 
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pathogen induced exacerbations in lung disease.[63,64] Diseased 
phenotypes may be modeled by directly culturing primary cells 
from diseased patients or alternatively, inflammation can be 
induced by stimulating cells with inflammatory proteins or 
Figure 4. Examples of advanced technology integrated in vitro models of the lung showing A) mechanical actuation, B) complex microfluidic airway 
design, C) compartmentalization of lung components and infectious agents and D) advanced electronic monitoring of ALI culture. A) Compartmentalized 
PDMS microchannels form the alveolar-capillary barrier. The device recreates physiological breathing movements by applying vacuum to the side cham-
bers and causing mechanical stretching of the PDMS membrane. Reproduced with permission.[171] Copyright 2010, AAAS. B) Anatomically inspired 
microfluidic acini-on-chip featuring an asymmetrical bipurification model of distal airways (blue arrows) and air-ducts (red arrows). Reproduced with 
permission.[177] Copyright 2019, Wiley. C) A microbial culture insert is inoculated with A. fumigatus on the left and P. aeruginosa on the right, facilitating 
volatile factor contact between the microbial cultures and air-exposed center lumens lined with bronchiolar epithelial cells. Scale bar is 250 µm. Repro-
duced with permission.[168] Copyright 2017, Nature Publishing Group. D) Effect of E Cigarette Emissions on Tracheal cells monitored at ALI using an 
organic electrochemical transistor. Integration of an ALI airway epithelium model into a flexible gate-OECT platform for ALI resistance sensing, which 
conforms to the cell secreted mucus. Reproduced with permission.[178] Copyright 2019, Wiley.
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cytokines implicated in disease pathology. For example, aller-
genic asthma-like lung inflammation can be induced with the 
cytokine IL-13, which is known to induce airway-hyperrespon-
siveness and goblet cell hyperplasia in vivo.[73,158] These models 
can also be used as drug discovery platforms by applying novel 
therapeutics to microchannels and measuring effects on epi-
thelial cell composition, function, and cytokine profile. Studies 
such as these, illustrate the importance of modelling complex 
aspects of the in vivo lung environment, such as physiological 
flow rate and breathing-induced mechanical strain. Organ-on-
chip technology paves the way for portable, multi-parametric, 
and simultaneous assay platforms, which increasingly makes 
the study of respiratory pathogens in healthy and diseased 
human airways more efficient and accessible.
5. Future Directions
Although substantial progress has been made in recent years 
toward 3D and technology integrated in vitro lung models, 
there remain some limitations or problems to address. For 
example, in the case of organoid or complex scaffold structures, 
there is limited capability in monitoring the cellular compo-
nents found within the core of the 3D systems. Secondly, in the 
case of ALI cultures, the present gold standards for monitoring 
epithelial integrity, such as TEER, require the apical surface to 
be submerged in an electrolyte/media. This negates the advan-
tages of ALI culturing method, as well as preventing any long 
term/real-time TEER measurements of any ALI culture. Some 
novel innovations and future prospective, which address these 
limitations, are highlighted below.
5.1. Conducting Polymer Scaffolds
As mentioned above, the use of polymer scaffolds and hydro-
gels in 3D cell culture has proven advantages such as increased 
viability, differentiation, and the ability to study cell–ECM inter-
actions. However, there also remain limitations in accurately 
assessing/monitoring the inner portions of these 3D structures. 
One solution to this is the fabrication of complex cell architec-
tures within conducting polymers, permitting the electronic 
monitoring of enclosed cell populations. Interestingly, in a 3D 
tissue engineered tubular model, the fabrication of conducting 
polymer scaffolds demonstrated the ability to monitor cell adhe-
sion, growth and migration in real-time, via material-integrated 
electronic sensing abilities.[180] This highlights the potential of 
scaffold systems to accurately monitor complex 3D architec-
tures in a dynamic and mid-throughput manner. One can see 
how this technology may be adapted or integrated into lung 
scaffolds for monitoring epithelial/endothelial permeability and 
immune cell adhesion/migration when performing pathogen 
challenge experiments. It is also possible to utilize hydrogels 
as biosensors by tuning them to detect pH, temperature, light, 
or electricity,[181] which can be particularly beneficial for use in 
microfluidic devices for creating on-chip readout systems. The 
field of bioelectronics, discussed below, looks promising for 
future application in monitoring cell and tissue culture in a 
non-invasive, label free, and real-time manner.
5.2. Advances in Flexible Electronics
A technology capable of conforming and electronically 
monitoring a range of complex 3D architectures, lies in the 
field of bioelectronics. Indeed, parallel to the rise of bio-
compatible and wearable electronic sensors in medical 
and commercial settings,[182,183] flexible electronics have 
also been implemented in a variety of in silico[184], in vivo, 
and in vitro research applications.[185] Of note are poly 
(3,4-ethlyenedioxythiophene) doped (p-type) with poly (styrene 
sulfonate) (PEDOT:PSS)-based electrodes or organic electro-
chemical transistors (OECTs). The detailed physical theory of 
OECT operation is explored elsewhere,[186,187] but such tech-
nology has been integrated into a variety of biological formats, 
including Transwell ALI culture,[178] planar and microfluidic 
devices,[188–191] PEDOT:PSS bio-scaffolds,[192,193] self-rolling 
sensors,[194] and neuromorphic devices.[195] In vivo examples 
include bioresorbable patches[196,197] and implantable electro-
corticography devices for monitoring neuronal epileptiform 
discharge.[198,199] In each of these applications, OECT devices 
have shown superior performance when compared to con-
ventional electrode recordings, including lower operational 
voltages, increased signal-to-noise ratio (SNR), and increased 
biocompatibility. Furthermore, OECTs display high capaci-
tance, low impedance, mechanical flexibility, chemical tuna-
bility, and optical transparency, making them ideal candidates 
for multiparametric sensing, simultaneous characterization 
with optical techniques and improved efficiency, and accuracy 
of data acquisition.[187,200,201] OECT devices have been used to 
study epithelial barrier formation and disruption,[202] stem cell 
differentiation,[203] and to detect analytes in human fluid sam-
ples for diagnostic purposes.[204] In the line of pathogen infec-
tion, the application of OECTs have been largely used to study 
food-borne or bacterial infection of intestinal[205] and kidney 
cell lines.[206] In relation to the respiratory epithelium, OECTs 
have been applied to the study of E-cigarette aerosol expo-
sure on human tracheal barrier integrity in ALI cultures[178] 
(Figure  4D) and conductivity of ion channels implicated in 
pulmonary disease.[207] Additionally, if biofunctionalized, 
OECTs, can achieve a high detection sensitivity of protein bio-
markers,[208] cell surface glycans,[209] and human viruses[210] 
which demonstrates the capability of this technology in 
advancing host–pathogen interaction studies.
6. Conclusions
Respiratory infection and related co-morbidities are one of the 
leading causes of death worldwide, while also contributing a 
substantial socio-economic burden. Given the recent SARS-
CoV-2 pandemic, it has become increasingly evident that more 
efficient and biomimetic in vitro systems are needed to improve 
the efficacy, reproducibility, and translatability of therapeutics, 
antivirals, and vaccines. Here, we have given an overview of 
the biological and immunological components responsible for 
respiratory epithelial barrier integrity in health and disease. 
Furthermore, we have given an overview of the most common 
respiratory pathogens, as well as traditional 2D and more com-
plex 3D in vitro models for studying host–respiratory pathogen 
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interactions. Great improvements have been made in recent 
years in the fields of tissue engineering, material science, and 
biotechnology that have enabled the production of complex 3D 
models. For example, improvements in hydrogel composites 
have allowed for improved differentiation, proliferation, and 
longevity of cell/tissue culture. Developments in microfluidic 
and microfabrication techniques have also contributed crucial 
knowledge on the importance of mechanical, biochemical, 
and spatiotemporal cues in replicating an entire organ system. 
Additionally chip technology permits the integration of mul-
tiple biosensors in a compact design which offers advantages 
such as speed of processing, detection, breadth of readout 
data, and device portability. Finally, with the rise in the field of 
flexible electronic biosensors, which have the ability to physi-
cally conform to a range of complex 3D architecture, give mul-
timodal, real time, and long term readouts, the future may see 
further integration of this technology with respiratory in vitro 
models.
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